Drugs / PEG-IFNα
PEG-IFNα
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05612581 | May 2023 → Oct 2024 | chronic hepatitis B virus infection | Vir Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02328755 | Jan 2015 → Mar 2019 | acute myeloid leukemia | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 27 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT06491563 | Aug 2024 → Dec 2026 expected | chronic hepatitis B virus infection | Brii Biosciences Limited | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06425341 | Jun 2024 → Aug 2026 overdue | chronic hepatitis B virus infection | Fujian Shengdi Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05771402 | Oct 2023 → Dec 2026 expected | autoimmune pulmonary disease due to PD-1 deficiency, chronic hepatitis B virus infection, interferon antiviral depressor | The Second Affiliated Hospital of Chongqing Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT05970289 | Aug 2023 → Jul 2025 overdue | chronic hepatitis B virus infection | Brii Biosciences Limited | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05734807 | Jul 2022 → Apr 2024 | chronic hepatitis B virus infection | Huahui Health | Completed | No outcome recorded |
| Phase 2 | NCT04856085 | Jul 2021 → Mar 2026 | chronic hepatitis B virus infection | Vir Biotechnology, Inc. | Completed | Met primary |
| Phase 2 | NCT04781647 | Feb 2021 → Dec 2022 | chronic hepatitis B virus infection | Assembly Biosciences | Terminated | Missed primary Stop: Business |
| Phase 41 trial | ||||||
| Phase 4 | NCT07573943 | May 2024 → Dec 2026 expected | chronic hepatitis B virus infection | The Second Affiliated Hospital of Chongqing Medical University | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06650852 Background | Oct 2024 → Jul 2026 overdue | chronic hepatitis B virus infection | Brii Biosciences Limited | Recruiting | No outcome recorded |
Press releases naming this drug 3 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pegIFNα | “This observation was translated into a proof-of-concept phase 1/2 clinical trial with long-acting IFN-α (pegylated IFN-α [pegIFNα]) in patients undergoing HCT for high-risk...” PMID 34607341 ↗ Dec 2021 |
| Known as | pegylated IFN-α | “This observation was translated into a proof-of-concept phase 1/2 clinical trial with long-acting IFN-α (pegylated IFN-α [pegIFNα]) in patients undergoing HCT for high-risk...” PMID 34607341 ↗ Dec 2021 |
| Known as | pegylated interferon alfa | “Here we provide a randomized evaluation of the small interfering RNA elebsiran, in combination with pegylated interferon alfa (PEG-IFNα), compared with PEG-IFNα monotherapy.” PMID 41203919 ↗ Nov 2025 |
| Known as | pegylated interferon alpha-2a | “This protocol is an open label, single arm, non-randomized, phase I / II clinical trial investigating the use of pegylated interferon alpha-2a (peg-IFN-α, Pegasys®, Genentech)...” NCT02328755 ↗ |
| Modality | Protein / enzyme biologic | “Biological: Peg-IFNα” NCT04781647 ↗ |
| Route | Subcutaneous | “It will be administered by subcutaneous injection every 14 days” NCT02328755 ↗ |